Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/4164—1,3-Diazoles
  • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
  • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2022—Organic macromolecular compounds
  • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
  • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/12—Drugs for disorders of the urinary system of the kidneys
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/06—Antiarrhythmics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/12—Antihypertensives

Definitions

• the present invention relates to a pharmaceutical for the prophylaxis or treatment of hypertension, a heart disease [angina pectoris, myocardial infarction, arrhythmia (including sudden death), heart failure, or cardiac hypertrophy], a kidney disease (diabetic nephropathy, glomerulonephritis, or nephrosclerosis), a cerebrovascular disease (cerebral infarction or intracerebral hemorrhage), or a vascular disorder (arteriosclerosis, restenosis after PTCA, or peripheral circulatory disturbance).
• a heart disease angina pectoris, myocardial infarction, arrhythmia (including sudden death), heart failure, or cardiac hypertrophy
• a kidney disease diabetic nephropathy, glomerulonephritis, or nephrosclerosis
• cerebrovascular disease Cerebral infarction or intracerebral hemorrhage
• a vascular disorder arteriosclerosis, restenosis after
• angiotensin II receptor antagonists and calcium antagonists are widely used as pharmaceuticals for the treatment or prophylaxis of hypertension, a heart disease, or the like.
• MR Mineralocorticoid receptors
• Angiotensin II receptor antagonists which are renin-angiotensin system inhibitors are particularly effective in renin-dependent hypertension and exhibit a protective activity against cardiovascular disorders and kidney disorders. Further, calcium antagonists antagonize (inhibit) the function of calcium channels so as to have a natriuretic activity in addition to a vasodilatory activity, and are therefore effective also in fluid retention (renin-independent) hypertension.
• diuretics are widely used as pharmaceuticals for the treatment or prophylaxis of hypertension, a heart disease, or the like.
• Diuretics are effective in the treatment of hypertension because of their diuretic effect. Therefore, it is expected that by using an MR antagonist and a diuretic in combination, multiple causes of high blood pressure can be suppressed simultaneously because of the diuretic activity of the diuretic, and a stable and sufficient therapeutic or prophylactic effect on hypertension is exhibited regardless of the causes of the disease.
• compound (I) 1-(2-Hydroxyethyl) -4-methyl-N-[4-(methylsulfonyl)phenyl]-5-[2-(trifluoromethyl)phenyl]-1H-pyrrole-3-carboxamide (hereinafter referred to as “compound (I)”) is disclosed in PTL 1 and PTL 2, and is known to be useful for treating hypertension, diabetic nephropathy, and the like.
• olmesartan medoxomil is an angiotensin II receptor antagonist, and is known to be useful as a pharmaceutical for treatment or the prophylaxis of hypertension, a heart disease, and the like (PTL 3).
• Olmesartan medoxomil is commercially available as Olmetec® tablet or Benicar®, each of which contains olmesartan medoxomil as an active ingredient in an amount of 5 mg, 10 mg, 20 mg, or 40 mg, and further contains low-substituted hydroxypropyl cellulose, hydroxypropyl cellulose, crystalline cellulose, lactose, and magnesium stearate as additives.
• amlodipine 3-ethyl-5-methyl-( ⁇ )-2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methylpyridine-3, 5-dicarboxylate (hereinafter referred to as “amlodipine”) is a known compound as an excellent calcium antagonist and is useful as a pharmaceutical for the treatment or prophylaxis of hypertension, a heart disease, and the like (PTL 4)
• Amlodipine is commercially available as Norvasc® tablets, which contain amlodipine besylate as an active ingredient in an amount of 3.47 mg or 6.93 mg (2.5 mg or 5 mg in terms of amlodipine) and further contains crystalline cellulose, anhydrous calcium hydrogen phosphate, carboxymethyl starch sodium, magnesium stearate, hydroxypropyl methyl cellulose, titanium oxide, talc, and carnauba wax as additives.
• hydrochlorothiazide 6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonami de 1,1-dioxide
• An object of the present invention is to provide a pharmaceutical for the prophylaxis or treatment of hypertension or a disease derived from hypertension, more specifically, to provide a pharmaceutical for the prophylaxis and/or treatment of hypertension, a heart disease [angina pectoris, myocardial infarction, arrhythmia (including sudden death), heart failure, or cardiac hypertrophy], a kidney disease (diabetic nephropathy, glomerulonephritis, or nephrosclerosis), a cerebrovascular disease (cerebral infarction or intracerebral hemorrhage), or a vascular disorder (arteriosclerosis, restenosis after PTCA, or peripheral circulatory disturbance) (particularly a pharmaceutical for the prophylaxis or treatment of hypertension).
• a heart disease angina pectoris, myocardial infarction, arrhythmia (including sudden death), heart failure, or cardiac hypertrophy
• a kidney disease diabetic nephropathy, glomerulone
• the present inventors found that by combining a specific MR antagonist with an angiotensin II receptor antagonist, a calcium antagonist, or a diuretic, an excellent blood pressure lowering activity is exhibited. Further, the present inventors found that such a pharmaceutical is extremely effective in the prophylaxis and/or treatment of hypertension, a heart disease [angina pectoris, myocardial infarction, arrhythmia (including sudden death), heart failure, or cardiac hypertrophy], a kidney disease (diabetic nephropathy, glomerulonephritis, or nephrosclerosis), a cerebrovascular disease (cerebral infarction or intracerebral hemorrhage), or a vascular disorder (arteriosclerosis, restenosis after PTCA, or peripheral circulatory disturbance).
• a heart disease angina pectoris, myocardial infarction, arrhythmia (including sudden death), heart failure, or cardiac hypertrophy]
• a kidney disease diabetic nephropathy
• the present invention provides the following (1) to (13).
• a pharmaceutical for the prophylaxis or treatment of hypertension or a disease derived from hypertension characterized by comprising
• a pharmaceutical for the prophylaxis or treatment of a disease selected from the group consisting of hypertension, a heart disease, angina pectoris, myocardial infarction, arrhythmia, sudden death, heart failure, cardiac hypertrophy, a kidney disease, diabetic nephropathy, glomerulonephritis, nephrosclerosis, a cerebrovascular disease, cerebral infarction, intracerebral hemorrhage, and a vascular disorder (arteriosclerosis, restenosis after PTCA, or peripheral circulatory disturbance), comprising one or more components selected from component (A), component (B), and component (C), and the mineralocorticoid receptor antagonist according to the above (1) as active ingredients.
• a disease selected from the group consisting of hypertension, a heart disease, angina pectoris, myocardial infarction, arrhythmia, sudden death, heart failure, cardiac hypertrophy, a kidney disease, diabetic nephropathy, glomerulonephritis, ne
• a pharmaceutical for the prophylaxis or treatment of hypertension and/or diabetic nephropathy comprising one or more components selected from component (A), component (B), and component (C), and the mineralocorticoid receptor antagonist according to the above (1) as active ingredients.
• a pharmaceutical for treating hypertension comprising one or more components selected from component (A), component (B), and component (C), and the mineralocorticoid receptor antagonist according to the above (1) as active ingredients.
• a pharmaceutical for treating diabetic nephropathy containing one or more components selected from a component (A), a component (B), and a component (C), and the mineralocorticoid receptor antagonist according to the above (1) as active ingredients.
• angiotensin II receptor antagonist is (5-methyl-2-oxo-1,3-dioxolan-4-yl) methyl 4-(1-hydroxy-1-methylethyl) -2-propyl-1-[2′-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]imidazole-5-carboxylate
• the calcium antagonist is a calcium antagonist selected from the group consisting of azelnidipine, amlodipine, benidipine, nitrendipine, manidipine, nicardipine, nifedipine, nisoldipine, cilnidipine, lercanidipine, niguldipine, nimodipine, aranidipine, efonidipine, barnidipine, felodipine, clevidipine, lacidipine, and nilvadipine.
• the diuretic is a diuretic selected from the group consisting of hydrochlorothiazide, methyclothiazide, benzylhydrochlorothiazide, trichloromethiazide, cyclopenthiazide, polythiazide, ethiazide, cyclothiazide, bendroflumethiazide, and hydroflumethiazide.
• the calcium antagonist is amlodipine.
• a pharmaceutical comprising a substance selected from the group consisting of compound (I), an atropisomer thereof, and a pharmacologically acceptable salt thereof for use in combination with one or more components selected from the following components (A) to (C):
• a pharmaceutical which comprises a substance selected from the group consisting of a compound (I), an atropisomer thereof, and a pharmacologically acceptable salt thereof, and enhances the activity of components (A) to (C) by comprising one or more components selected from the following components (A) to (C) in combination:
• a mineralocorticoid receptor antagonist which comprises a substance selected from the group consisting of a compound represented by the above formula (I), an atropisomer thereof, and a pharmacologically acceptable salt thereof, and component (A), component (B), or component (C) for producing the pharmaceutical; and a prophylaxis or treatment method (particularly a treatment method) for a disease, including administering effective amounts of a mineralocorticoid receptor antagonist which comprises a substance selected from the group consisting of a compound represented by the above formula (I), an atropisomer thereof, and a pharmacologically acceptable salt thereof, and component (A), component (B) or component (C) to a warm-blooded animal (particularly a human being) are provided.
• the pharmaceutical is provided as a pharmaceutical composition
• a mineralocorticoid receptor antagonist which comprises a substance selected from the group consisting of a compound represented by the above formula (I), an atropisomer thereof, and a pharmacologically acceptable salt thereof, and component (A), component (B) or component (C) as active ingredients
• this pharmaceutical composition may comprise one or more pharmaceutical additives.
• a pharmaceutical comprising an angiotensin II receptor antagonist, a calcium antagonist, or a diuretic, and an MR antagonist as active ingredients of the present invention has an excellent blood pressure lowering activity and also has low toxicity, and therefore is useful as a pharmaceutical ⁇ preferably a prophylactic agent or a therapeutic agent (particularly a therapeutic agent) for hypertension, a heart disease [angina pectoris, myocardial infarction, arrhythmia (including sudden death), heart failure, or cardiac hypertrophy], a kidney disease (diabetic nephropathy, glomerulonephritis, or nephrosclerosis), a cerebrovascular disease (cerebral infarction or intracerebral hemorrhage), or a vascular disorder (arteriosclerosis, restenosis after PTCA, or peripheral circulatory disturbance), more preferably a prophylactic agent or a therapeutic agent (particularly a therapeutic agent) for hypertension or a heart disease, and particularly preferably a prophylactic agent or a therapeutic agent (
• the pharmaceutical of the present invention is characterized by comprising a mineralocorticoid receptor antagonist which comprises a substance selected from the group consisting of a compound represented by the above formula (I), an atropisomer thereof, and a pharmacologically acceptable salt thereof, and
• the compound represented by the above formula (I), an atropisomer thereof, or a pharmacologically acceptable salt thereof serving as an active ingredient of the present invention is known, and can be produced by, for example, the method described in WO 2006/012642 (US Patent Publication No. US2008-0234270), WO 2008/056907 (US Patent Publication No. US2010-0093826), or the like.
• the compound (I) or an atropisomer thereof is preferably the following atropisomer compound (Ia).
• a substance selected from the compound represented by the above formula (I) or an atropisomer thereof a hydrate or a solvate can also be used.
• an atropisomer in pure form or an arbitrary mixture of atropisomers can also be used.
• angiotensin II receptor antagonist examples include biphenyl tetrazole compounds such as olmesartan medoxomil, olmesartan cilexetil, losartan, candesartan cilexetil, valsartan, and irbesartan, biphenyl carboxylic acid compounds such as telmisartan, eprosartan, and azilsartan, and the angiotensin II receptor antagonist is preferably a biphenyl tetrazole compound, more preferably olmesartan medoxomil, losartan, candesartan cilexetil, valsartan, or irbesartan, particularly preferably olmesartan medoxomil, losartan, or candesartan cilexetil, and most preferably olmesartan medoxomil.
• biphenyl tetrazole compounds such as olmesartan medoxom
• Olmesartan medoxomil is described in JP-A-5-78328, U.S. Pat. No. 5,616,599, and the like, and its chemical name is (5-methyl-2-oxo-1,3-dioxolan-4-yl)methyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[2′-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]imidazole-5-carboxylate, and olmesartan medoxomil as used herein encompasses a pharmacologically acceptable salt thereof.
• Losartan (DUP-753) is described in JP-A-63-23868, U.S. Pat. No. 5,138,069, and the like, and its chemical name is 2-butyl-4-chloro-1-[2′-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]-1H-imidazole-5-methanol, and losartan as used herein encompasses a pharmacologically acceptable salt thereof (losartan potassium salt or the like).
• Candesartan cilexetil is described in JP-A-4-364171, EP-459136, U.S. Pat. No. 5,354,766, and the like, and its chemical name is 1-(cyclohexyloxycarbonyloxy)ethyl-2-ethoxy-1-[2′-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]-1H-benzimidazole-7-carboxylate, and candesartan cilexetil as used herein encompasses a pharmacologically acceptable salt thereof.
• Valsartan (CGP-48933) is described in JP-A-4-159718, EP-433983, and the like, and its chemical name is (S)-N-valeryl-N-[2′-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl)valine, and valsartan as used herein encompasses a pharmacologically acceptable ester thereof or a pharmacologically acceptable salt thereof.
• Irbesartan (SR-47436) is described in JP-T-4-506222, WO 91-14679, and the like, and its chemical name is 2-N-butyl-4-spirocyclopentane-1-[2′-(tetrazol-5-yl)bipheny 1-4-ylmethyl]-2-imidazoline-5-one, and irbesartan as used herein encompasses a pharmacologically acceptable salt thereof.
• Eprosartan (SKB-108566) is described in U.S. Pat. No. 5,185,351 and the like, and its chemical name is 3-[1-(4-carboxyphenylmethyl)-2-n-butyl-imidazol-5-yl]-2-thienyl-methyl-2-propenoic acid, and eprosartan as used herein encompasses a carboxylic acid derivative thereof, a pharmacologically acceptable ester of a carboxylic acid derivative, or a pharmacologically acceptable salt thereof (eprosartan mesylate or the like).
• Telmisartan (BIBR-277) is described in U.S. Pat. No. 5,591,762 and the like, and its chemical name is 4′-[[4-methyl-6-(1-methyl-2-benzimidazolyl)-2-propyl-1-benzimidazolyl]methyl]-2-biphenylcarboxylic acid, and telmisartan as used herein encompasses a carboxylic acid derivative thereof, a pharmacologically acceptable ester of a carboxylic acid derivative, or a pharmacologically acceptable salt thereof.
• Azilsartan is described in JP-A-05-271228, U.S. Pat. No. 5,243,054, and the like, and its chemical name is 2-ethoxy-1 ⁇ [2′-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl ⁇ -1H-benzo[d]imidazole-7-carboxylic acid.
• the angiotensin II receptor antagonist of the present invention also encompasses optical isomers and mixtures of isomers thereof. Further, it also encompasses hydrates of the compounds.
• the calcium antagonist containing a 1,4-dihydropyridine-based compound to be used as the component (B) is a calcium antagonist characterized by having a 1,4-dihydropyridine partial structure or a partial structure chemically equivalent thereto in the molecule.
• As calcium antagonists containing a 1,4-dihydropyridine-based compound various agents have been proposed and are actually used in clinical practice, and therefore, those skilled in the art can select a suitable agent exhibiting the effect of the present invention.
• a calcium antagonist containing a 1,4-dihydropyridine-based compound for example, azelnidipine, amlodipine, benidipine, nitrendipine, manidipine, nicardipine, nifedipine, nisoldipine, cilnidipine, lercanidipine, niguldipine, nimodipine, aranidipine, efonidipine, barnidipine, felodipine, clevidipine, lacidipine, nilvadipine, or the like can be used, however, the calcium antagonist is not limited thereto.
• the type of the pharmacologically acceptable salt of the 1,4-dihydropyridine-based compound is not particularly limited and can be suitably selected by those skilled in the art.
• the pharmacologically acceptable salt may be either an acid addition salt or a base addition salt.
• metal salts including alkali metal salts such as sodium salts, potassium salts, and lithium salts, alkaline earth metal salts such as calcium salts and magnesium salts, aluminum salts, iron salts, zinc salts, copper salts, nickel salts, and cobalt salts; base addition salts such as amine salts including inorganic salts such as ammonium salts and organic salts such as t-octyl amine salts, dibenzylamine salts, morpholine salts, glucosamine salts, phenylglycine alkyl ester salts, ethylenediamine salts, N-methylglucamine salts, guanidine salts, diethylamine salts, triethylamine salts, dicyclohexylamine salts, N,N′-dibenzylethylenediamine salts, chloroprocaine salts, procaine salts, diethanolamine salts, N-benzylphenethylamine salts,
• the calcium antagonist containing a 1,4-dihydropyridine-based compound a hydrate or a solvate of the above-mentioned compound or a pharmacologically acceptable salt thereof may be used.
• the calcium antagonist containing a 1,4-dihydropyridine-based compound sometimes has one or more asymmetric carbon atoms in the molecule, however, an optical isomer or a stereoisomer such as a diastereoisomer in pure form based on the asymmetric carbon, or an arbitrary mixture of stereoisomers or a racemic mixture, or the like can also be used as the component (B).
• component (B) ( ⁇ )-2-amino-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 3-(1-diphenylmethylazetidin-3-yl)ester 5-isopropyl ester is preferred.
• the calcium antagonist containing a 1,4-dihydropyridine-based compound is more preferably amlodipine, and can be easily produced according to the method described in Japanese Patent No. 1401088 (U.S. Pat. No. 4,572,909) or the like.
• Amlodipine can form pharmacologically acceptable salts, and the present invention also encompasses these salts.
• the pharmacologically acceptable salt may be either an acid addition salt or a base addition salt. Examples thereof include besylates, hydrochlorides, hydrobromides, fumarates, citrates, tartrates, maleates, camsilates, lactates, mesylates, nicotinates, and gluconates.
• the salt is not limited thereto, but is preferably a besylate.
• the diuretic to be used as the component (C) is a known compound, and is described in, for example, U.S. Pat. No. 2,554,816, U.S. Pat. No. 2,980,679, U.S. Pat. No. 2,783,241, UK Patent No. 795,174, U.S. Pat. No. 2,835,702, UK Patent No. 851,287, U.S. Pat. No. 3,356,692, U.S. Pat. No. 3,055,904, U.S. Pat. No. 2,976,289, U.S. Pat. No. 3,058,882, Pharmacometrics, vol. 21, 607 (1982), U.S. Pat. No. 3,183,243, U.S. Pat. No.
• sulfonamide-based compound such as acetazolamide, methazolamide, ethoxzolamide, clofenamide, dichlorphenamide, disuflamide, mefruside, chlorthalidone, quinethazone, furosemide, clopamide, tripamide, indapamide, clorexolone, metolazone, xipamide, bumetanide, piretanide, or X-54; a thiazide-based compound such as hydrochlorothiazide, methylclothiazide, benzylhydrochlorothiazide, trichloromethiazide, cyclopenthiazide, polythiazide, ethiazide, cyclothiazide, bendroflumethiazide, or hydroflumethiazide; a phenoxyacetic acid-based compound such as ethacrynic acid,
• hydrochlorothiazide 6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide
• hydrochlorothiazide as used herein encompasses a pharmacologically acceptable salt thereof, and the salt can be, for example, a hydrogen halide salt such as a hydrofluoride, a hydrochloride, a hydrobromide, or a hydroiodide; a nitrate; a perchlorate; a sulfate; a phosphate; a C1-C4 alkane sulfonate which may be substituted with halogen such as a methanesulfonate, a trifluoromethanesulfonate, or an ethanesulfonate; a C6-C10 aryl sulfonate which may be substituted with C1-C4 alkyl such as a
• the diuretic of the present invention also encompasses optical isomers and mixtures of isomers thereof. Further, it also encompasses hydrates of the compounds.
• the phrase administered “simultaneously” is not particularly limited as long as it is an administration form capable of performing administration at substantially the same time, however, it is preferred to perform administration as a single composition.
• the phrase administered “separately at a time interval” is not particularly limited as long as it is an administration form capable of performing administration separately at different times, however, for example, it refers to that first, an MR antagonist is administered, and then, after a predetermined time, a calcium antagonist is administered, or first, a calcium antagonist or a diuretic is administered, and then, after a predetermined time, an MR antagonist is administered in the same manner as described above.
• a pharmaceutical composition for administering simultaneously or separately at a time interval the MR antagonist and the angiotensin II receptor antagonist, the calcium antagonist, or the diuretic of the present invention can further lower the blood pressure by allowing the MR antagonist and component (A), component (B), or component (C) to act as specifically described in the Examples of this description.
• the pharmaceutical of the present invention can be used for the prophylaxis or treatment (particularly treatment) of hypertension, a heart disease [angina pectoris, myocardial infarction, arrhythmia (including sudden death), heart failure, or cardiac hypertrophy], a kidney disease (diabetic nephropathy, glomerulonephritis, or nephrosclerosis), a cerebrovascular disease (cerebral infarction or intracerebral hemorrhage), or a vascular disorder (arteriosclerosis, restenosis after PTCA, or peripheral circulatory disturbance).
• a heart disease angina pectoris, myocardial infarction, arrhythmia (including sudden death), heart failure, or cardiac hypertrophy
• a kidney disease diabetic nephropathy, glomerulonephritis, or nephrosclerosis
• cerebrovascular disease Cerebral infarction or intracerebral hemorrhage
• a vascular disorder arteriosclerosis, reste
• the MR antagonist and the angiotensin II receptor antagonist, the calcium antagonist, or the diuretic serving as the active ingredients of the pharmaceutical composition of the present invention can be prepared in the form of separate unit dosage forms each containing a single agent alone, or can be prepared physically in the form of one unit dosage form by mixing these agents.
• the MR antagonist and the angiotensin II receptor antagonist, the calcium antagonist, or the diuretic serving as the active ingredients of the pharmaceutical composition of the present invention can be administered orally in the form of a tablet, a capsule, a granule, a powder, a syrup, or the like, or parenterally in the form of an injection, a suppository, or the like, which is produced according to a known method using the respective agents by themselves, or by using also a suitable pharmacologically acceptable additive such as an excipient, a lubricant, a binder, a disintegrant, an emulsifier, a stabilizer, a corrigent, or a diluent.
• the MR antagonist, and the components (A), (B), and (C) to be comprised in the pharmaceutical of the present invention are agents to be generally administered orally
• excipient examples include organic excipients including sugar derivatives such as lactose, white soft sugar, glucose, mannitol, and sorbitol; starch derivatives such as corn starch, potato starch, pregelatinized starch, and dextrin; cellulose derivatives such as crystalline cellulose; gum arabic; dextran; and pullulan; and inorganic excipients including silicate derivatives such as light anhydrous silicic acid, synthetic aluminum silicate, calcium silicate, and magnesium metasilicate aluminate; phosphates such as calcium hydrogen phosphate; carbonates such as calcium carbonate; and sulfates such as calcium sulfate.
• sugar derivatives such as lactose, white soft sugar, glucose, mannitol, and sorbitol
• starch derivatives such as corn starch, potato starch, pregelatinized starch, and dextrin
• cellulose derivatives such as crystalline cellulose
• gum arabic such as dextran
• lubricant examples include stearic acid; stearic acid metal salts such as calcium stearate and magnesium stearate; talc; colloidal silica; waxes such as beeswax and spermaceti; boric acid; adipic acid; sulfates such as sodium sulfate; glycol; fumaric acid; sodium stearyl fumarate; sodium benzoate; D,L-leucine; lauryl sulfates such as sodium lauryl sulfate and magnesium lauryl sulfate; silicates such as anhydrous silicic acid and silicate hydrate; and the above-mentioned starch derivatives.
• stearic acid stearic acid metal salts such as calcium stearate and magnesium stearate
• talc colloidal silica
• waxes such as beeswax and spermaceti
• boric acid adipic acid
• sulfates such
• binder examples include hydroxypropyl cellulose, hydroxypropyl methyl cellulose, polyvinylpyrrolidone, macrogol, and compounds similar to the above-mentioned excipients
• disintegrant examples include cellulose derivatives such as low-substituted hydroxypropyl cellulose, carboxymethyl cellulose, calcium carboxymethyl cellulose, and internally crosslinked sodium carboxymethyl cellulose; cross-linked polyvinylpyrrolidone; and chemically modified starches and celluloses such as carboxymethyl starch and sodium carboxymethyl starch.
• emulsifier examples include colloidal clays such as bentonite and Veegum; metal hydroxides such as magnesium hydroxide and aluminum hydroxide; anionic surfactants such as sodium lauryl sulfate and calcium stearate; cationic surfactants such as benzalkonium chloride; and nonionic surfactants such as polyoxyethylene alkyl ether, polyoxyethylene sorbitan fatty acid ester, and sucrose fatty acid ester.
• colloidal clays such as bentonite and Veegum
• metal hydroxides such as magnesium hydroxide and aluminum hydroxide
• anionic surfactants such as sodium lauryl sulfate and calcium stearate
• cationic surfactants such as benzalkonium chloride
• nonionic surfactants such as polyoxyethylene alkyl ether, polyoxyethylene sorbitan fatty acid ester, and sucrose fatty acid ester.
• stabilizer examples include p-hydroxybenzoate esters such as methyl paraben and propyl paraben; alcohols such as chlorobutanol, benzyl alcohol, and phenyl ethyl alcohol; benzalkonium chloride; phenols such as phenol and cresol; thimerosal; dehydroacetic acid; and sorbic acid.
• corrigent examples include sweeteners such as sodium saccharin and aspartame; acidulants such as citric acid, malic acid, and tartaric acid; and flavors such as menthol, lemon, and orange flavors.
• diluent examples include materials generally used as a diluent such as lactose, mannitol, glucose, sucrose, calcium sulfate, calcium phosphate, hydroxypropyl cellulose, microcrystalline cellulose, water, ethanol, polyethylene glycol, propylene glycol, glycerol, starch, polyvinylpyrrolidone, magnesium metasilicate aluminate, and mixtures thereof.
• the doses of the mineralocorticoid receptor antagonist, the angiotensin II receptor antagonist, the calcium antagonist, and the diuretic serving as the active ingredients of the pharmaceutical composition of the present invention can vary depending on various conditions such as the activities of the respective agents, and the symptoms, age, body weight, etc. of a patient.
• each agent can be administered at a dose of 0.1 mg (preferably 0.5 mg) as a lower limit and 1000 mg (preferably 500 mg) as an upper limit in the case of oral administration, and at a dose of 0.01 mg (preferably 0.05 mg) as a lower limit and 100 mg (preferably 50 mg) as an upper limit in the case of parenteral administration to a human adult 1 to 6 times per day depending on the symptoms, and the agents can be administered simultaneously or separately at a time interval.
• the ratio of the doses of the MR antagonist and the angiotensin II receptor antagonist, the calcium antagonist, or the diuretic serving as the active ingredients of the pharmaceutical composition of the present invention can also largely vary, but the weight ratio thereof can be in the range of 1:1-10000 to 10000:1-10000, preferably in the range of 1:1-1000 to 1000:1-1000, more preferably in the range of 1:1-100 to 100:1-100.
• the doses in the case where the mineralocorticoid receptor antagonist serving as the active ingredient of the pharmaceutical composition of the present invention is (S)-1-(2-hydroxyethyl)-4-methyl-N-[4-(methylsulfonyl)phenyl]-5-[2-(trifluoromethyl)phenyl]-1H-pyrrole-3-carboxamide, the angiotensin II receptor antagonist is olmesartan medoxomil, the calcium antagonist is amlodipine, and the diuretic is hydrochlorothiazide can vary depending on various conditions such as the activities of the respective agents, and the symptoms, age, body weight, etc.
• (S)-1-(2-hydroxyethyl)-4-methyl-N-[4-(methylsulfonyl)phenyl]-5-[2-(trifluoromethyl)phenyl]-1H-pyrrole-3-carboxamide can be administered at a daily dose of 1.0 mg to 10 mg (preferably 2.5 mg to 5 mg)
• olmesartan medoxomil can be administered at a daily dose of 5 mg to 80 mg (preferably 10 mg to 40 mg)
• amlodipine can be administered at a daily dose (on the free form basis) of 2.5 mg to 20 mg (preferably 5 mg to 10 mg)
• hydrochlorothiazide can be administered at a daily dose (on the free form basis) of 5 mg to 50 mg (preferably 12.5 mg to 25 mg) to a human adult 1 to 6 times per day (preferably once per day) depending on the symptoms.
• the dose of the MR antagonist can be somewhat lower than in the case where it is used as a pressure lowering agent which is its original usage, and the dose thereof can be further decreased by the excellent effect of combined administration thereof with the angiotensin II receptor antagonist, the calcium antagonist, or the diuretic.
• a test substance was orally administered for 6 weeks.
• the test substance was suspended in 0.5% methyl cellulose solution and administered at a volume of 2 mL/kg.
• an 8% salt diet (FR-2 containing 8% NaCl, manufactured by Funabashi Farm Co., Ltd.) was given ad libitum from the start of administration of the test substance.
• the composition of the groups and the administered test substances [in parentheses] are as follows.
• Group 3 compound (Ia) administration group [compound (Ia) (1.0 mg/kg)]
• Group 4 olmesartan medoxomil administration group [olmesartan medoxomil (10 mg/kg)]
• Group 5 combined administration group [compound (Ia) (1.0 mg/kg)+olmesartan medoxomil (10 mg/kg)]
• a test substance was orally administered for 6 weeks.
• the test substance was suspended in 0.5% methyl cellulose solution and administered at a volume of 2 mL/kg.
• an 8% salt diet (FR-2 containing 8% NaCl, manufactured by Funabashi Farm Co., Ltd.) was given ad libitum from the start of administration of the test substance.
• the composition of the groups, the administered test substances [in parentheses], and the number of rats (n) per group are as follows.
• a test substance was orally administered for 6 weeks.
• the test substance was suspended in 0.5% methyl cellulose solution and administered at a volume of 2 mL/kg.
• an 8% salt diet (FR-2 containing 8% NaCl, manufactured by Funabashi Farm Co., Ltd.) was given ad libitum from the start of administration of the test substance.
• the composition of the groups, the administered test substances [in the parentheses], and the number of rats (n) per group are as follows.
• Systolic blood pressure was measured by using a noninvasive sphygmomanometer for rats and mice (BP-98A, Softron Co., Ltd.) during the trough period at the 6th week of administration of the test substance (on day 40 from the start of administration of the test substance).
• urine collection for 24-hour was performed using a metabolic cage (2100-R, Watanabe Isolator Systems Co., Ltd.), and the daily urinary protein excret ion per body weight was calculated.
• a powder having the above formulation is mixed and tableted with a tableting machine, thereby forming a tablet (300 mg/tablet).
• This tablet can be sugar-coated as needed.
• a pharmaceutical for the prophylaxis or treatment of hypertension or a disease derived from hypertension is obtained. More specifically, a pharmaceutical for the prophylaxis and/or treatment of hypertension, a heart disease [angina pectoris, myocardial infarction, arrhythmia (including sudden death), heart failure, or cardiac hypertrophy], a kidney disease (diabetic nephropathy, glomerulonephritis, or nephrosclerosis), a cerebrovascular disease (cerebral infarction or intracerebral hemorrhage), or a vascular disorder (arteriosclerosis, restenosis after PTCA, or peripheral circulatory disturbance) is obtained.
• a heart disease angina pectoris, myocardial infarction, arrhythmia (including sudden death), heart failure, or cardiac hypertrophy]
• a kidney disease diabetic nephropathy, glomerulonephritis, or nephrosclerosis
• cerebrovascular disease Cerebral in

Landscapes

• Health & Medical Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Public Health (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Epidemiology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Cardiology (AREA)
• Heart & Thoracic Surgery (AREA)
• Diabetes (AREA)
• Urology & Nephrology (AREA)
• Hematology (AREA)
• Emergency Medicine (AREA)
• Endocrinology (AREA)
• Vascular Medicine (AREA)
• Obesity (AREA)
• Hospice & Palliative Care (AREA)
• Biomedical Technology (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Priority Applications (1)

Applications Claiming Priority (3)

Related Parent Applications (1)

Related Child Applications (1)

Publications (1)

Family

ID=52393246

Family Applications (2)

Family Applications After (1)

Country Status (5)

Families Citing this family (3)

Citations (1)

Family Cites Families (39)

• 2014
  • 2014-07-18 ES ES14830125T patent/ES2847904T3/es active Active
  • 2014-07-18 WO PCT/JP2014/069135 patent/WO2015012205A1/ja active Application Filing
  • 2014-07-18 JP JP2015528260A patent/JP6422868B2/ja active Active
  • 2014-07-18 EP EP14830125.2A patent/EP3025711B1/en active Active
• 2016
  • 2016-01-14 US US14/996,064 patent/US20160206593A1/en not_active Abandoned
• 2017
  • 2017-10-02 US US15/723,097 patent/US10111858B2/en active Active
• 2018
  • 2018-04-26 JP JP2018084951A patent/JP6532984B2/ja active Active

Patent Citations (2)

Non-Patent Citations (3)

Also Published As

Similar Documents

Legal Events